Business Wire

Wish Granted Payment Institution License for the EU

Share

ContextLogic B.V. (“CLBV”), a Dutch subsidiary of ContextLogic Inc. (d/b/a/ Wish) (NASDAQ: WISH), today announced it has been granted a Payment Services License by the Dutch Central Bank (De Nederlandsche Bank N.V., “DNB”).

The new Payment Services License will enable Wish to process transactions and increase control over the payments value chain in a compliant manner, while also reducing reliance on third parties. In addition to the Netherlands, the license will be passported to the other European markets where Wish operates. Wish will initially utilize the license to pay its EU merchants directly and will explore other payment services in the future. The license will not have an impact on consumers in Europe.

“The granting of this license is an exciting first step towards becoming a payments services provider in Europe,” said Ward Homminga, Regional General Manager of CLBV. “Not only will it deliver cost savings as we eventually maintain control over our payments processes, but it will also provide a framework to explore opportunities in the payment services space.”

The provision of payment services is subject to the European Payment Services Directive 2 (“PSD2”) as implemented in the European countries in which CLBV operates. In view of such implementation, CLBV applied for a license to act as a payment institution. As a payments institution, CLBV is now under the supervision of DNB and, as such, is required to comply with rules applicable to payment institutions.

About Wish:

Wish brings an affordable and entertaining shopping experience to millions of consumers around the world. Since our founding in San Francisco in 2010, we have become one of the largest global ecommerce platforms, connecting millions of value-conscious consumers in over 100 countries to over half a million merchants globally. Wish combines technology and data science capabilities and an innovative discovery-based mobile shopping experience to create a highly-visual, entertaining, and personalized shopping experience for its users. For more information about the company or to download the Wish mobile app, visit www.wish.com or follow @Wish on Facebook, Instagram and TikTok or @WishShopping on Twitter and YouTube.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact could be deemed forward-looking, including, but not limited to, statements regarding Wish's outlook, priorities, strategic direction, expectations, and growth opportunities. In some cases, forward-looking statements can be identified by terms such as “anticipates,” “believes,” “could,” “estimates,” “expects,” “guidance,” “intends,” “may,” “outlook,” “plans,” “potential,” “predicts,” “projects,” “seeks,” “should,” “will,” “would” or similar expressions and the negatives of those terms. These forward-looking statements are subject to risks, uncertainties, and assumptions. If the risks materialize or assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. Further information on these and additional risks that could affect Wish’s results is included in its filings with the Securities and Exchange Commission (“SEC”), including its Annual Report for 2020 on Form 10-K filed on March 25, 2021 and its Form 10-Q for the first quarter of 2021 filed on May 12, 2021, and future reports that Wish may file with the SEC from time to time, which could cause actual results to vary from expectations. Any forward-looking statement made by Wish in this news release speaks only as of the day on which Wish makes it. Wish assumes no obligation to, and does not currently intend to, update any such forward-looking statements after the date of this release.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media contact:
Carys Comerford-Green, Wish
press@wish.com

Investor contact:
Dennis Walsh, Wish
ir@wish.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Moody’s Analytics Earns #2 Overall Ranking in Chartis Research STORM505.8.2021 16:15:00 CEST | Press release

Moody’s Analytics is #2 in the inaugural Chartis Research STORM50 (Statistical Techniques, Optimization frameworks and Risk Models) ranking of the world’s leading providers of quantitative solutions for the financial industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210805005744/en/ Chartis’ STORM50 ranking measures the strength of solutions in quantitative modeling and software, assessing the level of innovation and the quality of the underlying computational infrastructure. The scoring is based on five criteria: breadth and coverage, impact, computational infrastructure, innovation, and strategy. In addition to the #2 ranking overall, Moody’s Analytics placed first in 14 of 55 categories, including Breadth & Coverage, Impact, Strategy, and Innovation, evidencing the depth of the company’s modeling expertise. “The inaugural Chartis Research STORM50 ranking highlights our ability to deliver an integrated view of risk

Ultivue Announces Co-Marketing Agreement with Fluidigm for Biomarker Imaging Solutions for Precision Medicine5.8.2021 15:30:00 CEST | Press release

Ultivue, Inc. and Fluidigm Corporation (Nasdaq:FLDM) today announced a co-marketing agreement in which the companies will offer customers a comprehensive portfolio of workflow solutions for biomarker discovery and drug development. Ultivue, a leader in advancing precision medicine solutions by accelerating tissue biomarker discovery and validation develops unique assays for use in multiplex immunofluorescence imaging and analysis. Its proprietary InSituPlex® technology is designed for fast and comprehensive exploration of biologically-relevant markers combined with same slide-H&E analysis in precious tissue samples. Fluidigm is a leader in high-parameter imaging for the clinical translational research and clinical testing markets. It’s Imaging Mass Cytometry™ (IMC™) technology is designed for highly multiplexed targeted interrogation of tissue sections for 40 or more protein markers in one scan, with distinct non-overlapping signals from element-labeled antibodies detected simultaneous

Andersen Global Strengthens Puerto Rican Coverage with Tax and Advisory Firm5.8.2021 15:30:00 CEST | Press release

Andersen Global adds dimension to its platform in Puerto Rico with the addition of collaborating firm AFS CPA Group LLC (AFS), solidifying its presence in the country with tax and legal coverage. AFS provides tax and advisory services to clients including individuals and small and large businesses, serving a variety of industries such as legal, medical, food and restaurants, apparel, marketing, technology, non-profit and homeowners associations. The firm, established in 2000 by Founder and Managing Partner Antonio Sécola, is based in Gurabo and offers tax, financial, investment and cash management services as well as outsourcing and payroll functions. “As an Arthur Andersen alumnus, I look forward to rejoining the culture and working with like-minded individuals who are committed to serving clients best-in-class solutions,” Antonio said. “Our firm is dedicated to providing the highest quality service, and this collaboration further supplements our ability to deliver seamless solutions

Precision for Medicine and Trialbee Partner to Advance Clinical Trials for Complex Therapies and Speed Shift Toward Precision Medicine5.8.2021 15:22:00 CEST | Press release

Clinical research organization Precision for Medicine and Trialbee, a patient matching and enrollment platform, are addressing complexities in clinical development through a new partnership that will accelerate the future of precision medicine. Trialbee’s advanced analytics will play a critical role in matching patients to trials conducted by Precision for Medicine and extending recruitment to a more diverse, targeted patient community for the development of complex, personalized medicine. The partnership expands Precision for Medicine’s ability to match patients who could benefit from life-saving therapies, especially those who could be a match for trials in oncology, rare and orphan diseases, including cell or gene therapy trials. Trialbee enables accurate and fast enrollment, improving the patient journey and helping to meet patient enrollment timelines. The Precision Site Network, which includes both academic and non-academic sites across North America, Europe, and Australia, can c

Loop Energy Enters Joint Market Development Agreement With Técnicas Reunidas to Accelerate the Commercialization of Hydrogen-Powered Vehicles5.8.2021 14:00:00 CEST | Press release

Loop Energy (TSX:LPEN), a developer and manufacturer of hydrogen fuel cell-based solutions, announces their joint market development agreement with Técnicas Reunidas (TR) – a global provider of services for investors in hydrogen infrastructure based in Madrid, Spain. Under this agreement, both parties will aim to secure future opportunities that require both TR’s hydrogen know-how and Loop Energy’s fuel cell technology. The initial scope of this joint market agreement focuses on providing hydrogen-based solutions to several key vertical markets: transport agencies, truck, transit and coach bus service fleets, materials handling, warehouse and port logistics including drayage, urban delivery services and stationary power applications. With the assistance of TR’s on-site production and supply equipment, creating hydrogen both via water electrolysis and steam reforming of natural gas, biogas or bioethanol, Loop will be able to provide more convenient and cost-effective hydrogen solutions

Moody's to Acquire RMS, Leader in Climate & Natural Disaster Risk5.8.2021 13:18:00 CEST | Press release

Moody's Corporation (NYSE: MCO) and RMS announced today that they have entered into a definitive agreement for Moody’s to acquire RMS, a leading global provider of climate and natural disaster risk modeling and analytics, for approximately $2.0 billion from Daily Mail and General Trust plc (LON: DMGT). The acquisition will immediately increase Moody’s insurance data and analytics business to nearly $500 million in revenue and will accelerate the development of the Company’s global integrated risk capabilities to address the next generation of risk assessment. With over 400 risk models covering 120 countries, RMS is the world’s leading provider of climate and natural disaster risk modeling serving the global property and casualty (P&C) insurance and reinsurance industries. For the fiscal year ending September 30, 2021, RMS is expected to generate revenue of approximately $320 million1 and adjusted operating income of approximately $55 million1. "Today’s leaders face a complex, interlink

Final Results from the Longest Hereditary Angioedema Study of Active Treatment Duration Conducted to Date Support the Sustained Safety and Efficacy of TAKHZYRO ® (lanadelumab) Injection for Long-Term Prevention of Hereditary Angioedema Attacks5.8.2021 13:00:00 CEST | Press release

Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE:TAK) (“Takeda”) today announced the publication of the final results from the Phase 3 HELP (Hereditary Angioedema Long-term Prophylaxis) Study™ Open-label Extension (OLE) designed to evaluate the long-term safety (primary endpoint) and efficacy of TAKHZYRO® (lanadelumab) 300mg every two weeks for up to 2.5 years. The study results show that preventative treatment with TAKHZYRO markedly reduced the frequency of hereditary angioedema (HAE) attacks in patients 12 years of age and older who received treatment for a mean duration of almost 2.5 years (29.6 months; 8.2 standard deviation).1 The data were published online this month in the journal Allergy. Secondary endpoints of the study showed the mean (min;max) HAE attack rate observed in the study population (N=209) was reduced by 87.4 percent (-100; 852.8) overall versus baseline, and attacks requiring acute treatment (N=106) were reduced by 93.4 percent (-100; -52.8).1 Reductions were

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom